Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO Earnings Yield (Joel Greenblatt) % is 7.07% as of Mar. 2026, which is 84% above its 10-year median of 3.84. The stock has 1 warning sign investors should review. Among 213 Medical Diagnostics & Research companies, Invitro International ranks better than 95.31% on this metric.
Invitro International's Enterprise Value for the quarter that ended in Mar. 2026 was $1.02 Mil.
Invitro International's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $0.07 Mil. Invitro International's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 7.07%.
The historical rank and industry rank for Invitro International's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
IVRO'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -48.64 Med: 3.84 Max: 27.29
Current: 13.14
During the past 9 years, the highest Earnings Yield (Joel Greenblatt) of Invitro International was 27.29%. The lowest was -48.64%. And the median was 3.84%.
IVRO's Earnings Yield (Joel Greenblatt) % is ranked better than 95.31% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.2
vs IVRO: 13.14
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Invitro International's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Invitro International (OTCPK:IVRO) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Invitro International Earnings Yield (Joel Greenblatt) % Related Terms
Invitro International Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Invitro International's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International Earnings Yield (Joel Greenblatt) % Chart
For the Diagnostics & Research subindustry, Invitro International's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International Earnings Yield (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Invitro International's Earnings Yield (Joel Greenblatt) % falls into.
Invitro International Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Invitro Internationals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Sep. 2025 is calculated as
Invitro International's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 7.07% mean?
Invitro International (IVRO) has a Earnings Yield (Joel Greenblatt) % of 7.07% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Invitro International and its competitors. This is 84% above median its historical median of 3.84. According to the industry distribution chart, Invitro International ranks #10 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 4.7%.
Is Invitro International's Earnings Yield (Joel Greenblatt) % too high?
Invitro International's current Earnings Yield (Joel Greenblatt) % of 7.07% is 84% above median its 10-year median of 3.84. Based on the distribution chart, Invitro International ranks #10 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Invitro International's Earnings Yield (Joel Greenblatt) % compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #10 out of 213 companies for Earnings Yield (Joel Greenblatt) %. This places Invitro International in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good Earnings Yield (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Invitro International and its competitors. Invitro International's current Earnings Yield (Joel Greenblatt) % is 7.07%, which is 84% above median its own 10-year median of 3.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 7.07%, which is 84% above median its 10-year median of 3.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Invitro International (IVRO), the current Earnings Yield (Joel Greenblatt) % is 7.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
